Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sadahiro Naka

Showing results (31-40 of 41) with videos related to

Pageof 5
Sort By:
EJNMMI Radiopharmacy and Chemistry|December 27, 2025
Scale-up production of [<sup>211</sup>At]PSMA-5 using automated synthesizer for Investigator-Initiated clinical trialSadahiro Naka, Tadashi Watabe, Yoshifumi Shirakami, et al.
Asia Oceania Journal of Nuclear Medicine & Biology|July 28, 2020
Evaluation of D-isomer of <sup>18</sup>F-FBPA for oncology PET focusing on the differentiation of glioma and inflammationNobuto Hirai, Tadashi Watabe, Shushi Nagamori, et al.
Breast Cancer Research : BCR|March 7, 2025
Preclinical evaluation of <sup>64</sup>Cu-labeled cetuximab in immuno-PET for detecting sentinel lymph node metastasis in epidermal growth factor receptor-positive breast cancerTakeshi Usui, Tomohiro Miyake, Tadashi Watabe, et al.
EJNMMI Radiopharmacy and Chemistry|July 31, 2020
Automated [<sup>18</sup>F]PSMA-1007 production by a single use cassette-type synthesizer for clinical examinationSadahiro Naka, Tadashi Watabe, Kenta Kurimoto, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 12, 2023
Immuno-PET and Targeted α-Therapy Using Anti-Glypican-1 Antibody Labeled with <sup>89</sup>Zr or <sup>211</sup>At: A Theranostic Approach for Pancreatic Ductal AdenocarcinomaTadashi Watabe, Kazuya Kabayama, Sadahiro Naka, et al.
Clinical Nuclear Medicine|September 8, 2023
Evaluation of LAT1 Expression in Patients With Lung Cancer and Mediastinal Tumors: 18F-FBPA PET Study With Immunohistological ComparisonTadashi Watabe, Naoko Ose, Sadahiro Naka, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 2, 2023
Initial Evaluation of [Tadashi Watabe, Sadahiro Naka, Mitsuaki Tatsumi, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 25, 2025
First-in-Human Study of [<sup>211</sup>At]NaAt as Targeted α-Therapy in Patients with Radioiodine-Refractory Thyroid Cancer (Alpha-T1 Trial)Tadashi Watabe, Kosuke Mukai, Sadahiro Naka, et al.
International Journal of Molecular Sciences|November 9, 2024
Evaluation of Targeted Alpha Therapy Using [<sup>211</sup>At]FAPI1 in Triple-Negative Breast Cancer Xenograft ModelsKaori Abe, Tadashi Watabe, Kazuko Kaneda-Nakashima, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 21, 2026
Diagnostic impact of interpretation criteria for [<sup>18</sup>F]PSMA-1007 PET/CT: Prospective comparison with CT and bone scanYuwei Liu, Koji Hatano, Motohide Uemura, et al.
Pageof 5

Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
EJNMMI Radiopharmacy and Chemistry|December 27, 2025
Scale-up production of [<sup>211</sup>At]PSMA-5 using automated synthesizer for Investigator-Initiated clinical trialSadahiro Naka, Tadashi Watabe, Yoshifumi Shirakami, et al.
Asia Oceania Journal of Nuclear Medicine & Biology|July 28, 2020
Evaluation of D-isomer of <sup>18</sup>F-FBPA for oncology PET focusing on the differentiation of glioma and inflammationNobuto Hirai, Tadashi Watabe, Shushi Nagamori, et al.
Breast Cancer Research : BCR|March 7, 2025
Preclinical evaluation of <sup>64</sup>Cu-labeled cetuximab in immuno-PET for detecting sentinel lymph node metastasis in epidermal growth factor receptor-positive breast cancerTakeshi Usui, Tomohiro Miyake, Tadashi Watabe, et al.
EJNMMI Radiopharmacy and Chemistry|July 31, 2020
Automated [<sup>18</sup>F]PSMA-1007 production by a single use cassette-type synthesizer for clinical examinationSadahiro Naka, Tadashi Watabe, Kenta Kurimoto, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 12, 2023
Immuno-PET and Targeted α-Therapy Using Anti-Glypican-1 Antibody Labeled with <sup>89</sup>Zr or <sup>211</sup>At: A Theranostic Approach for Pancreatic Ductal AdenocarcinomaTadashi Watabe, Kazuya Kabayama, Sadahiro Naka, et al.
Clinical Nuclear Medicine|September 8, 2023
Evaluation of LAT1 Expression in Patients With Lung Cancer and Mediastinal Tumors: 18F-FBPA PET Study With Immunohistological ComparisonTadashi Watabe, Naoko Ose, Sadahiro Naka, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 2, 2023
Initial Evaluation of [Tadashi Watabe, Sadahiro Naka, Mitsuaki Tatsumi, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 25, 2025
First-in-Human Study of [<sup>211</sup>At]NaAt as Targeted α-Therapy in Patients with Radioiodine-Refractory Thyroid Cancer (Alpha-T1 Trial)Tadashi Watabe, Kosuke Mukai, Sadahiro Naka, et al.
International Journal of Molecular Sciences|November 9, 2024
Evaluation of Targeted Alpha Therapy Using [<sup>211</sup>At]FAPI1 in Triple-Negative Breast Cancer Xenograft ModelsKaori Abe, Tadashi Watabe, Kazuko Kaneda-Nakashima, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 21, 2026
Diagnostic impact of interpretation criteria for [<sup>18</sup>F]PSMA-1007 PET/CT: Prospective comparison with CT and bone scanYuwei Liu, Koji Hatano, Motohide Uemura, et al.
Pageof 5